

Please amend the paragraph at page 8, lines 7-23, as follows:

Sub  
E2

wherein R<sup>1</sup> is selected from the group consisting of lower alkyl, lower alkenyl, (hydroxy)lower alkyl, lower alkynyl, phenyl, benzyl and 2-thienyl, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are the same or different and are each selected from the group consisting of hydrogen and lower alkyl, each R<sup>6</sup> is individually selected from the group consisting of hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro and halo, n is 1-3, R<sup>7</sup> is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, X is selected from the group consisting of oxy and thio, Y is selected from the group consisting of carbonyl (CH<sub>2</sub>)<sub>1-3</sub>, (CH<sub>2</sub>)<sub>1-3</sub>SO<sub>2</sub> or (CH<sub>2</sub>)<sub>1-3</sub>C(O), and Z is selected from the group consisting of hydroxy, lower alkoxy optionally substituted with OH, 4-pyridyl, amino, lower alkylamino, di(lower alkyl)amino, or N-morpholino; amino, lower alkylamino, [(carboxy)(lower alkyl)]amino, di(lower alkyl)amino and phenylamino, [or Y-Z is (CH<sub>2</sub>)<sub>1-3</sub>R<sup>8</sup> wherein R<sup>8</sup> is] OH, (C<sub>2</sub>-C<sub>4</sub>)acyloxy, SO<sub>3</sub>H, PO<sub>4</sub>H<sub>2</sub>, N(NO)(OH), SO<sub>2</sub>NH<sub>2</sub>, PO(OH)NH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub><sup>+</sup> or tetrazolyl or a pharmaceutically acceptable salt thereof. Lower alkyl, alkenyl, alkanoyl, etc. indicates a branched, cyclic or straight chain C<sub>1</sub>-C<sub>6</sub> group, preferably a C<sub>1</sub>-C<sub>4</sub> group, including cycloalkyl and (cycloalkyl)alkyl. (Hydroxy)lower alkyl or alkoxy is preferably 1- or 2- hydroxyethyl.

#### IN THE CLAIMS

Please substitute the claim set in the appendix entitled Clean Version of Pending Claims for the previously pending claim set. The substitute claim set is intended to reflect amendment of previously pending claim 1, 10, 20, and 21. The specific amendments to individual claims are detailed in the following marked up set of claims.

Please amend claim 1 as follows:

A



Docket No. 00103.022US1

UC Case No. 1999-238-3 (CIP)

**Clean Version of Amended Specification Paragraphs**

**INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER**

Applicant: Dennis A. Carson et al.

Serial No.: 09/634,207

**The paragraph at page 3, line 18 to page 4, line 4, as amended:**

a' wherein R<sup>1</sup> is lower alkyl, lower alkenyl, (hydroxy)lower alkyl, lower alkynyl, phenyl, benzyl or 2-thienyl, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are the same or different and are each hydrogen or lower alkyl; each R<sup>6</sup> is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, n is 1-3, R<sup>7</sup> is hydrogen, lower alkyl or lower alkenyl, X is oxy and thio, Y is carbonyl, (CH<sub>2</sub>)<sub>1-3</sub>, (CH<sub>2</sub>)<sub>1-3</sub>C(O), or (CH<sub>2</sub>)<sub>1-3</sub>SO<sub>2</sub> and Z is (ω-(4-pyridyl)(C<sub>2</sub>-C<sub>4</sub> alkoxy), (ω-((R<sup>8</sup>)(R<sup>9</sup>) amino)(C<sub>2</sub>-C<sub>4</sub> alkoxy), wherein R<sup>8</sup> and R<sup>9</sup> are each H, (C<sub>1</sub>-C<sub>3</sub>)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R<sup>8</sup>), S or nonperoxide O; an amino acid ester of (ω-(HO)(C<sub>2</sub>-C<sub>4</sub>))alkoxy, N(R<sup>8</sup>)CH(R<sup>8</sup>)CO<sub>2</sub>H, 1'-D-glucuronyloxy, OH, (C<sub>2</sub>-C<sub>4</sub>)acyloxy, SO<sub>3</sub>H, PO<sub>4</sub>H<sub>2</sub>, N(NO)(OH), SO<sub>2</sub>NH<sub>2</sub>, PO(OH)NH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub><sup>+</sup> or tetrazolyl; or a pharmaceutically acceptable salt thereof.

[ **The paragraph at page 8, lines 7-23, as amended:**

a<sup>2</sup> wherein R<sup>1</sup> is selected from the group consisting of lower alkyl, lower alkenyl, (hydroxy)lower alkyl, lower alkynyl, phenyl, benzyl and 2-thienyl, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are the same or different and are each selected from the group consisting of hydrogen and lower alkyl, each R<sup>6</sup> is individually selected from the group consisting of hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro and halo, n is 1-3, R<sup>7</sup> is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, X is selected from the group consisting of oxy and thio, Y is selected from the group consisting of carbonyl (CH<sub>2</sub>)<sub>1-3</sub>, (CH<sub>2</sub>)<sub>1-3</sub>SO<sub>2</sub> or (CH<sub>2</sub>)<sub>1-3</sub>C(O), and Z is selected

Q<sup>2</sup> from the group consisting of hydroxy, lower alkoxy optionally substituted with OH, 4-pyridyl, amino, lower alkylamino, di(lower alkyl)amino, or N-morpholino; amino, lower alkylamino, amino, di(lower)alkylamino and phenylamino, OH, (C<sub>2</sub>-C<sub>4</sub>)acyloxy, SO<sub>3</sub>H, PO<sub>4</sub>H<sub>2</sub>, N(NO)(OH), SO<sub>2</sub>NH<sub>2</sub>, PO(OH)NH<sub>2</sub>, OCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub><sup>+</sup> or tetrazolyl or a pharmaceutically acceptable salt thereof. Lower alkyl, alkenyl, alkanoyl, etc. indicates a branched, cyclic or straight chain C<sub>1</sub>-C<sub>6</sub> group, preferably a C<sub>1</sub>-C<sub>4</sub> group, including cycloalkyl and (cycloalkyl)alkyl. (Hydroxy)lower alkyl or alkoxy is preferably 1- or 2-hydroxyethyl.

---